Companies › Risen (Suzhou) Pharma Tech
2 active drug programs in 3 registered trials: 1 Phase 3, 1 Phase 1, 1 Phase 2; Oncology, Neurology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JS105 PIK3CA inhibitor | PIK3CA | Phase 3 | Breast Cancer; Advanced Solid Tumors | Feb 2027 |
| RP902 | – | Phase 2 | Mild Cognitive Impairment (MCI) | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06208410 | JS105 | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
| NCT07579884 | RP902 | Phase 2 | Mild Cognitive Impairment (MCI) | Neurology | May 2029 |
| NCT07207070 | JS105 | Phase 3 | Breast Cancer | Oncology | May 2029 |
iOnctura AB Science Italfarmaco Faeth Therapeutics SK Life Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.